Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Smith & Nephew Snats ( (SNN) ) has issued an announcement.
On 1 April 2026, Smith & Nephew granted deferred share bonus awards to Chief Executive Officer Deepak Nath and Chief Financial Officer John Rogers, deferring half of their 2025 annual bonuses into share awards that are scheduled to vest on 15 March 2029, with dividend-equivalent shares accruing over the vesting period. The awards were priced using an average market price of £12.744 per share, reinforcing pay-for-performance alignment for the top executives.
On the same date, the company issued performance share awards under its Global Share Plan 2020 to Nath, Rogers and a wider group of senior managers, with maximum-share awards vesting in March 2029 subject to performance measured from 1 January 2026 to 31 December 2028 and dividend-equivalent accruals. These grants, also priced at £12.744, further link leadership rewards to multi-year operational and market performance, potentially impacting future dilution but supporting long-term strategic focus.
Smith & Nephew also made grants under its Restricted Share Plan 2024 on 1 April 2026, with awards vesting in equal tranches over three years and carrying dividend-equivalent rights. For Nath and Rogers, vesting is additionally subject to a judgment-based underpin that allows the Remuneration Committee to scale back outcomes, including to zero, based on overall financial results, regulatory sanctions, ESG issues, major safety incidents or material reputational damage, signalling a stronger governance overlay on executive pay.
The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company, listed in the US as Smith & Nephew Snats, that develops and markets orthopaedics, sports medicine, advanced wound management and other surgical products. Its equity incentive plans use ordinary shares listed in London, aligning senior leadership remuneration with long-term shareholder value and regulatory requirements in its core healthcare markets.
Average Trading Volume: 878,212
Technical Sentiment Signal: Buy
Current Market Cap: $13.57B
See more insights into SNN stock on TipRanks’ Stock Analysis page.